戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 s obtained by modification of the amino acid D-penicillamine.
2 lticenter trial of high-dose versus low-dose D-penicillamine.
3 se MG had recently been provoked by the drug D-penicillamine.
4  2-year time period in patients treated with D-penicillamine.
5 id (3), a cyclized N-protected derivative of D(-)-penicillamine.
6                                              D-Penicillamine(2,5)-enkephalin (DPDPE) is a potent opio
7 pioid receptor agonists, deltorphin II, and [D-penicillamine(2,5)]-enkephalin.
8       By contrast the delta-opioid ligand [2-D-penicillamine, 5-D-penicillamine]enkephalin (DPDPE) ha
9 lied model was verified by exposing worms to D-penicillamine and menadione.
10 Cysteine differs from the antiarthritis drug D-penicillamine by only two methyl groups on the beta-ca
11 ne of a series of FSDs (N-acetyl-L-cysteine, D-penicillamine, captopril, L-cysteine, or reduced gluta
12 binds tightly to the active site zinc, while D-penicillamine catalyzes metal removal.
13 ase, we treated mice with a copper chelator, D-(-)-penicillamine (D-PEN), starting immediately follow
14 m 3 RCTs examining high-dose versus low-dose D-penicillamine (D-Pen Trial), recombinant human relaxin
15 ticancer therapy with a novel combination of D-penicillamine (D-pen) and Idarubicin (Ida) in a synthe
16                       The antiarthritis drug D-penicillamine (D-PEN) catalyzes zinc(II) transfer from
17 ects and subjects previously reported in the D-penicillamine (D-Pen) trial.
18          In contrast, the antiarthritis drug D-penicillamine, D-PEN, which differs from D-Cys only by
19 +)-doped quantum dots (Qdots) decorated with D-penicillamine (DPA-MnQdots).
20 trolled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective.
21 th PBC who had received ineffective therapy (D-penicillamine [DPCA] or placebo) for 5.6 +/- 0.07 year
22 he delta-opioid ligand [2-D-penicillamine, 5-D-penicillamine]enkephalin (DPDPE) had no effect on thes
23 A for 2 days followed by treatment with oral D-penicillamine for 90 days.
24 fficacy, whereas the results of therapy with D-penicillamine have been disappointing.
25 articipated in the High-Dose Versus Low-Dose D-Penicillamine in Early Diffuse SSc trial.
26  drug (Thalidomide) and false negative drug (D-penicillamine) in the conventional mouse embryonic ste
27 s and provides insight into the mechanism of D-penicillamine inhibition.
28 ulfasalazine, auranofin, intramuscular gold, D-penicillamine, methotrexate, and/or azathioprine).
29        The effects of other drugs, including D-penicillamine, nonsteroidal antiinflammatory drugs (NS
30                          Trientine (TRI) and D-penicillamine (PEN) are used to treat copper overload
31 esis of a series of N-terminal dipeptides of D(-)-penicillamine, prepared from the synthon 3-formyl-2
32                                              D-penicillamine protected against advanced glycation end
33 cles for NO, the NO donor S-nitroso-N-acetyl-D-penicillamine (SNAP) was encapsulated within poly(lact
34                                   Antecedent D-penicillamine therapy may have been protective against
35                   The duration of the use of D-penicillamine was significantly associated with improv
36 ning molecules, L-cysteine, glutathione, and D-penicillamine, were studied separately, and it was fou
37                                   Similarly, d-penicillamine, which inhibits lysyl oxidase enzymatic